Nature-based solutions for urban expansion: Integrating ecosystem services into the delineation of growth boundaries
In: Habitat international: a journal for the study of human settlements, Band 124, S. 102575
5 Ergebnisse
Sortierung:
In: Habitat international: a journal for the study of human settlements, Band 124, S. 102575
In: Growth and change: a journal of urban and regional policy, Band 54, Heft 1, S. 45-73
ISSN: 1468-2257
AbstractThe advancing global urbanization puts great pressure on the society and ecosystem, especially in developing countries. Reasonable land‐use policies adapted to local conditions are the key issues to prevent disordered urban expansion. Multi‐scenario simulation provides a new perspective for differentiated policy formulation based on regional heterogeneity. Regarding the Shaanxi Province, a rapid urbanized area with high spatial heterogeneity in western China, as the study case, we tracked its past land‐use changes and predicted the characteristics of urban expansion using the Future Urban‐Regional Environment Simulation model. We found that (1) during the past 35 years, built‐up land evidently increased accompanied by the loss of cropland, grassland, and unused land. (2) The urban expansion mainly will occur in the areas with flat terrain under three scenarios. (3) The urban expansion will transit into the "requiring land from mountains" pattern in the future, which means that it will gradually spread to areas with higher slopes. (4) Differentiated and optimal development patterns are proposed for different subregions by accounting the loss of ecosystem service in the procedure of urban expansion. This research can help local governments formulate differentiated future macro control of territorial spatial planning to optimize subregional land development.
Front-of-pack (FoP) labelling on foods is recommended by the World Health Organization (WHO) to address the growing global burden of diet-related noncommunicable diseases (NCDs), but this policy has not yet been implemented in China. The aim of this study was to ascertain key stakeholders' views on barriers and facilitators to developing a feasible and acceptable FoP labelling policy in the Chinese context. Semistructured interviews were used to elicit opinions from diverse representatives in roles of FoP labelling policy influence. Participants were identified by purposive and snowball sampling. The Consolidated Framework for Implementation Research (CFIR) was adopted to facilitate data collection and analysis. Themes and subthemes were generated using deductive and inductive approaches. Thirty participants were interviewed. The major barriers were the absence of national contextual analysis, perceived complexity of the process of policy development, disagreement on a preferred FoP labelling format, cost for the food industry, low priority compared to food safety policies, lack of existing regulatory framework or authorised nutrient profiling system, limited knowledge of FoP labelling, and the lack of planning and engagement with stakeholders. Facilitators included existing prerequisites, experiences and lessons from the pilot, policy coherence with Healthy China 2030, and support from external agents (e.g., WHO). Further efforts are required to develop and collate evidence to demonstrate the scientific, legal, and political feasibility of introducing effective FoP labelling.
BASE
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale.
BASE
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types.
BASE